Literature DB >> 19513617

Treatment of hemangioma by transfection of antisense VEGF gene.

Shengguo Shan1, Guang Shan, Duanlian Zhang.   

Abstract

The effect of transfection of antisense vascular endothelial growth factor (VEGF) gene on the growth of hemangioma was studied. A total of 49 cases of capillary hemangiomas of the skin were collected. Immunohistochemical method was used to detect the expression of PCNA in hemangioma tissues. According to the finding, 49 cases of hemangiomas fell into proliferating phase (27 cases) and involuting phase (22 cases) respectively. Another 5 cases of normal skin tissues adjacent to the tumor tissues served as control. Immunohistochemical staining was performed to detect the expression of VEGF in the tumor tissues and the normal tissues. The average absorbance (A) values and the average positive area rate of VEGF were measured by image analysis system (HPIAS-2000). Endothelial cells from the tumor tissues in proliferating phase were cultured. Eukaryotic expression vector was constructed by sub-cloning, and transfected into human hemangioma endothelial cells by using cation liposome as vector. The expression of VEGF mRNA and protein was detected by RT-PCR and indirect immunofluorescence assay (IFA), respectively, and the biological characteristics of the transfected endothelial cells were examined by MTT assay and flow cytometry (FCM) after transfection. Immunohistochemical results showed that the expression of VEGF in proliferating endothelial cells was remarkably higher than those in involuting endothelial cells and normal endothelial cells (P<0.01), but there was no significant difference in the expression of VEGF between involuting endothelial cells and normal ones (P>0.01). Electrophoresis and sequencing indicated that the eukaryotic expression vector containing antisense VEGF gene, i.e. pcDNA3.1-VEGF, was successfully constructed. After VEGF antisense RNA recombinant was transfected into hemangioma endothelial cells, RT-PCR revealed that the expression of VEGF mRNA in pcDNA-VEGF (V) group and blank group was obviously higher than that in pcDNA-VEGF (A) group, and that the expression of endogenous VEGF mRNA in pcDNA-VEGF (A) group was significantly inhibited. Immunohistochemical result demonstrated that, compared with blank group, there was statistically significant difference between pcDNA-VEGF (A) and pcDNA-VEGF (V) groups (P<0.01), but there was no significant difference between pcDNA-VEGF (V) group and blank group (P>0.05). The activity of endothelial cell proliferation was reduced significantly after transfection, and obvious apoptosis occurred in hemangioma endothelial cells after transfection of antisense VEGF. It was suggested that VEGF plays an important role in the pathological change of hemangiomas by promoting endothelial cell proliferation and angiogenesis. Antisense VEGF gene transfection could effectively inhibit the growth of hemanioma endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513617     DOI: 10.1007/s11596-009-0314-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  16 in total

1.  Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro.

Authors:  Zhong-Ping Gu; Yun-Jie Wang; Yu Wu; Jin-Ge Li; Nong-An Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 2.  VEGF-targeted therapy in metastatic renal cell carcinoma.

Authors:  Brian I Rini
Journal:  Oncologist       Date:  2005-03

Review 3.  The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle.

Authors:  A M Dvorak; D Feng
Journal:  J Histochem Cytochem       Date:  2001-04       Impact factor: 2.479

Review 4.  VEGF blocking therapy in the treatment of cancer.

Authors:  Julia Glade-Bender; Jessica J Kandel; Darrell J Yamashiro
Journal:  Expert Opin Biol Ther       Date:  2003-04       Impact factor: 4.388

5.  The HIF-2alpha/VEGF pathway activation in cutaneous capillary haemangiomas.

Authors:  Alexandra Giatromanolaki; Vasiliki Arvanitidou; Athanasios Hatzimichael; Constantinos Simopoulos; Efthimios Sivridis
Journal:  Pathology       Date:  2005-04       Impact factor: 5.306

6.  Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.

Authors:  J E Nör; J Christensen; D J Mooney; P J Polverini
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 7.  Specific gene suppression using antisense strategy for growth suppression of glioma.

Authors:  Akira Matsuno; Tadashi Nagashima
Journal:  Med Electron Microsc       Date:  2004-09

8.  Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium.

Authors:  J A Nagy; D R Senger; H F Dvorak; A M Dvorak
Journal:  J Histochem Cytochem       Date:  1995-04       Impact factor: 2.479

Review 9.  Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.

Authors:  T L Underiner; B Ruggeri; D E Gingrich
Journal:  Curr Med Chem       Date:  2004-03       Impact factor: 4.530

10.  p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway.

Authors:  Pawan Kumar; April I Miller; Peter J Polverini
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

View more
  2 in total

1.  Expression of HLA-G in hemangioma and its clinical significance.

Authors:  Guang Shan; Tian Tang; Duanlian Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

2.  Detection of p53 and Bcl-2 expression in cutaneous hemangioma through the quantum dot technique.

Authors:  Tian Tang; Duan-Lian Zhang
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.